Some states don’t have substitution laws--find out which ones.

Pharma and payers often disagree over how U.S. states should address substitutions of low-cost versions of biologic drugs.

Many states have already enacted laws dealing with substitution, but some markets have held out.

  • What are the “hurdles” biosimilar product substitution will face in the US?
  • Which states are lacking substitution laws?

DRG’s expert analysts have developed a NEW infographic to answer these questions.

Download

 

 

Download

 

How Glympse Bio oversubscribed their Series B funding amidst the pandemic

View Now